News

Implementation of Scheme of Arrangement and resignation and appointment of directors

Jun 14, 2018 -

Adelaide, 14 June 2018: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the scheme of arrangement between RHS and its shareholders (“Scheme”) has today been implemented. Implementation follows approval of the Scheme by RHS shareholders at the Scheme meeting held on 22 May 2018 and by the Federal Court of Australia on 29 May 2018.

Read More

Lodgement of Federal Court orders with ASIC and suspension of trading in RHS shares

May 30, 2018 -

Adelaide, 30 May, 2018. RHS Limited (ASX: RHS) (“RHS” or “the Company”) announces that it has lodged the Federal Court orders approving the scheme of arrangement under which PerkinElmer Holdings Pty Ltd, being a wholly owned subsidiary of PerkinElmer, Inc., will acquire all of the issued shares in RHS (Scheme) with the Australian Securities and Investments Commission. A copy of the Court’s orders are attached to this announcement.

Read More

Federal Court approves RHS Scheme

May 29, 2018 -

Adelaide, 29 May 2018: RHS Limited (ASX: RHS) is pleased to announce that the Federal Court of Australia has today made orders approving the scheme of arrangement under which PerkinElmer Holdings Pty Ltd, being a wholly owned subsidiary of PerkinElmer, Inc., will acquire all of the issued shares in RHS.

Read More

Results of RHS Scheme Meeting

May 22, 2018 -

RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that its shareholders have voted to approve the scheme of arrangement (Scheme) under which it is proposed that PerkinElmer Holdings Pty Ltd, being a wholly owned subsidiary of PerkinElmer, Inc., will acquire all of the issued shares in RHS. 97.13% of RHS shareholders present and voting at the Scheme Meeting (whether in person or by proxy, attorney or corporoate representative) voted in favour of the resolution to approve the Scheme; and 99.97% of the votes cast at the Scheme meeting (whether in person or by proxy, attorney or corporoate representative) were in favour of the resolution to approve the Scheme.

Read More

RHS Scheme of Arrangement

May 11, 2018 -

The Scheme Booklet for the Scheme Meeting was released to ASX on 18 April 2018 and dispatched to RHS shareholders on 20 April 2018. The Scheme Meeting to consider and vote on the Scheme has been convened for 11.00am (Adelaide time) on Tuesday, 22 May 2018. Shareholders may vote in person at the Scheme Meeting, or, if they are unable to attend the Scheme Meeting in person, they may vote by using the Proxy Form or by a duly authorised attorney. Proxy Forms must be received by no later than 11.00am (Adelaide time) on Sunday, 20 May 2018.

Read More

RHS Scheme Booklet dispatched to Shareholders

Apr 20, 2018 -

RHS Limited announced that today, Friday, 20 April 2018, it will dispatch to shareholders the Scheme Booklet, and personalised Proxy Form for the Scheme Meeting in relation to the previously announced Scheme of Arrangement. The Scheme Booklet will also be accompanied by the Company's Annual Report for the financial year ended 31 December 2017.

Read More

RHS Scheme Booklet registered with Australian Securities & Investments Commission

Apr 18, 2018 -

On 26 February 2018, RHS Limited announced that it had entered into a Scheme Implementation Agreement with PerkinElmer Inc, under which PerkinElmer proposes to acquire all RHS Shares by way of a scheme of arrangement. The Scheme Booklet for the proposed Scheme has now been registered with the Australian Securities and Investments Commission, and is expected to be dispatched to RHS Shareholders by Friday, 20 April 2018.

Read More

Annual Report 2017 and Appendix 4G

Apr 13, 2018 -

RHS has released the 2017 Annual Report and Appendix 4G today, 13th April 2018.

Read More

Annual General Meeting Extension

Mar 29, 2018 -

Australian Securities and Investments Commission has granted an extension of the period of time in which RHS must hold its annual general meeting for its financial year ended 31 December 2017. Pursuant to the extension granted by ASIC, the latest date on which RHS may hold its AGM has been extended by 2 months, from 31 May 2018 to 31 July 2018.

Read More

PerkinElmer to acquire RHS for 28 cents per share

Feb 26, 2018 -

RHS Limited is pleased to announce that it has entered into a binding Scheme Implementation Agreement with PerkinElmer, Inc. for the acquisition by PerkinElmer of all of the issued share capital of RHS by way of a Scheme of Arrangement (“Scheme”) for $0.28 per share.

Read More

Business Update December Quarter 2017

Jan 31, 2018 -

RHS commercial and scientific teams are readying for full commercial launch of PG-Seq™ with the first external clinical validation study complete and the second underway and expected to be completed during the March quarter. In parallel with validation of PG-Seq™ on the most commonly used sequencer in IVF clinics, RHS has validated PG-Seq™ on the significantly cheaper Illumina MiniSeq sequencer.

Read More

Second Ghent study demonstrates DOPlify™ suitability for liquid biopsy applications

Dec 11, 2017 -

RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that the results from a second University of Ghent single cell Whole Genome Amplification (WGA) kit comparison have been published in Nature Scientific Reports, with the results confirming that RHS’ DOPlify™ works robustly on cells prepared according to standard non-invasive prenatal or cancer testing protocols.

Read More

RHS demonstrates advanced performance for NGS product PG-Seq™

Nov 27, 2017 -

Repromed releases validation data for non-invasive embryo testing being co-developed with RHS at ASRM 2017 meeting. Also released at the same meeting were the validation results for the new RHS product PG-Seq™ that confirming test accuracy. RHS has been able to quadruple the throughput of PG-Seq™ compared to competitor kits, as well as validate PG-Seq™ on a significantly cheaper Illumina sequencer to target clinics considering bringing embryo testing in-house.

Read More

RHS & Monash IVF Lead the Field in Non-Invasive Embryo Screening (Bioshares)

Nov 17, 2017 -

RHS is working with Monash IVF to develop a non-invasive screening process. Results presented at the 2017 American Society of Reproductive Medicine meeting in San Antonio, USA showed a very high correlation with the current approach, which takes a biopsy of the embryo.

Read More

September Quarterly Business Update 2017

Oct 30, 2017 -

RHS releases performance validation data for its Next Generation Sequencing product PG-Seq™. Company also readies for increasing commercial activities with key in-house appointments and restructuring of resources. Quarter on quarter revenues maintained with cash on hand at 20 September 2017 of $1.39 Million.

Read More

RHS Releases Validation Data for NGS Product PG-Seq™

Oct 17, 2017 - latest news

RHS completes extensive validation of its Next Generation Sequencing product PG-Seq™ PG-Seq™ enters clinical validation at external sites ahead of full commercial product launch Adelaide, 17 October 2017: RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to release the performance data for PG-Seq™, its complete Next Generation Sequencing solution for Pre-implantation Genetic Testing, at the Fertility Society of Australia meeting currently being held in Adelaide, South Australia.

Read More

RHS wins HWA Lab competition

Oct 13, 2017 -

RHS takes out first price in the inaugural HWA Lab competition, providing RHS with additional funding to advance software development to accompany DOPlify™ RHS presenting at key National and International reproductive medicine meetings

Read More

RHS Expands Management Expertise

Aug 18, 2017 -

RHS Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce it has appointed Alwin Hui to the newly created position of Chief Commercial Officer.

Read More

June Quarterly Business Update 2017

Aug 01, 2017 -

RHS Limited's Quarter on Quarter forecast has been maintained; cash on hand at 30 June 2017 was $1.99m. The company's commercial and scientific resources bolstered as interest in products and genomic services escalates.

Read More

‘SA fertile ground for some’ - The Advertiser

Jul 14, 2017 -

In the Business Daily section of The Advertiser, Saturday July 8 2017, Cameron England wrote that RHS Ltd (formerly Reproductive Health Science Ltd) shares “have more than doubled with an April announcement of research which confirmed that the company’s DOPlify™ technology was 'world leading' putting a rocket under the share price”.

Read More

RHS Business Update, July 2017

Jul 11, 2017 -

RHS Limited has introduced a new product named PG-Seq™ at the European Society for Human Reproduction and Embryology (ESHRE) meeting held in Geneva. PG-Seq™ is a complete Pre-implantation Genetic Screening (PGS) solution using Next Generation Sequencing (NGS) that includes RHS’ DOPlify™ whole genome amplification, NGS library preparation reagents and software for data analysis.

Read More

RHS Teams Up with Monash IVF for Novel IVF Screening Technique (Bioshares)

Jul 04, 2017 -

RHS (formerly Reproductive Health Science)(RHS: $0.155) has teamed up with one of the majors in Australia in the IVF market, Monash IVF Group, to develop a new way to conduct pre-implantation genetic (PGS) screening.

Read More

Monash IVF Group and RHS Joint Media Release

Jun 29, 2017 -

Following performance validation, Repromed are using DOPlify™, for non-invasive PGS in a clinical trial

Read More

Two Application Scientist roles available with RHS

Jun 26, 2017 -

* Progressive company with a global focus * Seeking outstanding, passionate and enthusiastic candidates * Join a great team working within a collaborative environment RHS Ltd has an immediate requirement for two full-time Application Scientists. This is your opportunity to join a progressive and innovative company with over ten years of technical experience, two launched products and clinical services in the field of advanced single cell genomic technologies.

Read More

RHS Moves into Early Cancer Detection (Bioshares)

Jun 06, 2017 -

The quest to improve treatment and survival outcomes in oncology has progressed with the introduction of antibody therapies over the last 10 years and breakthroughs with immunotherapy over the last five years.

Read More

2017 RHS AGM Results and Presentations

May 29, 2017 - latest news

The results of the 2017 RHS AGM held on Friday 26th May 2017 are now available for review.

Read More

2017 RHS Annual General Meeting and release of 2016 Annual Report

Apr 26, 2017 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) has announced the Annual General Meeting for 2017 will be held on Friday, 26th May at their facilities located at 40-46 West Thebarton Road, Thebarton SA.

Read More

RHS Presentations at International Conference on Preimplantation Genetic Diagnosis, Valencia

Mar 30, 2017 - latest news

RHS is pleased to announce that it has been selected to present at the 16th International Conference on Preimplantation Genetic Diagnosis, organized by the Preimplantation Genetic Diagnosis International Society in Valencia. Company CSO Dr Melinda Jasper delivered two oral presentations on Wednesday, 29h of March 2017.

Read More

RHS Presentation at Biotech Showcase, San Francisco

Jan 11, 2017 - latest news

RHS is pleased to announce that it has been selected to present at 9th Annual Biotech Showcase in San Francisco. Non-Executive Chairman Dr David Brookes will deliver a 30 minutes presentation at 2.30 PM on Wednesday, 11th of January 2017.

Read More

RHS raises international profile, increases revenues and strengthens clinical expertise

Dec 16, 2016 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to report that following the relocation of Flinders Fertility to the TechInSA Incubator alongside RHS, previously announced to the market in the RHS ASX release of 21st November, Flinders Fertility has achieved RTAC accreditation of their facility, commenced IVF services on schedule and restored RHS’ PGS service provision. The co-location with RHS provides a unique opportunity for scientific exchange and direct clinical feedback on the RHS service provision and product suitability for IVF applications.

Read More

RHS Presentation at Australia Biotech Invest 2016

Oct 26, 2016 -

Adelaide, 26th October 2016: Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that CEO Dr Michelle Fraser will present today at the Australia Biotech Invest 2016 in Melbourne.

Read More

Placement and a fully underwritten non-renounceable rights issue raising A$1.5m

Sep 05, 2016 - latest news

On Monday, 5th September 2016 Reproductive Health Science Ltd (“RHS or the “Company”) announced a placement of 7,000,000 shares at $0.075 per share, through Taylor Collison Limited, to sophisticated investors raising $525,000 before costs ("Placement") and a fully underwritten one (1) for five (5) non‐renounceable rights issue to raise approximately A$990,000 (before expenses) (“Rights Issue”).

Read More

DOPlify™ Launch Presentation 23rd August 2016

Aug 25, 2016 - latest news

Dr Melinda Jasper, Chief Scientific Officer, Reproductive Health Science gave a presentation at the DOPlify™ Launch event held on Tuesday, 23rd August 2016

Read More

DOPlify™ Investor Presentation

Aug 25, 2016 - latest news

The investor presentation on the latest product from Reproductive Health Science (ASX:RHS), DOPlify™ , has just been released on the ASX today, 25th August 2016

Read More

Adelaide biotech company Reproductive Health Science Ltd to launch latest product to global market

Aug 17, 2016 - latest news

Adelaide, August 2016: Publicly listed Adelaide biotech company Reproductive Health Science Ltd (ASX:RHS) is launching its second product, DOPlify™ onto the global market.

Read More

RHS Presentation at Bioshares Biotech Summit, NZ

Aug 05, 2016 -

Dr Michelle Fraser, CEO Reproductive Health Science presented, at the 12th Bioshares Biotech Summit held in Queenstown, NZ

Read More

RHS Poster Presentation at ESHRE 2016 Helsinki

Jul 05, 2016 -

RHS are currently in Helsinki at the ESHRE Conference for 2016 and have been selected to present their poster titled 'Next Generation Sequencing (NGS) metrics following DOP-PCR whole genome amplification (WGA) of single and multi-cell samples for PGS'.

Read More

EmbryoCellect™ Performance Data Published and DOPlify™ Launched

Jul 04, 2016 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) has announced the release of a report on the validation of EmbryoCellect™ using euploid and aneuploid single cell and 5-10 cell aliquots.

Read More

‘RHS - Positive Results Start to Emerge from IVF Clinic Customers’

Jun 01, 2016 -

The latest Bioshares Newsletter has just been released, Edition 649 27th May 2016, which provides an article about RHS.

Read More

Results of the RHS Annual General Meeting 2016

May 25, 2016 -

The results of today's RHS Annual General Meeting for 2016 are now available for review.

Read More

Reproductive Health Science presented two posters at PGDIS in May 2016

May 23, 2016 -

Reproductive Health Science had two poster presentations at the recent Preimplantation Genetic Diagnosis International Society (PGDIS) Congress held in Bologna in May 2016.

Read More

The RHS Annual General Meeting is to be held on 25th May 2016

Apr 27, 2016 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) has announced the Annual General Meeting for 2016 will be held on Wednesday, 25th May at their facilities located at 40-46 West Thebarton Road, Thebarton SA.

Read More

The next EmbryoCellect™ training course date has been announced

Apr 19, 2016 -

The next EmbryoCellect™practical hands-on training course will be held in Adelaide, South Australia from Monday 22nd August to Thursday 25th August.

Read More

Fertility hopes for RHS tests

Apr 12, 2016 - latest news

ADELAIDE listed company Reproductive Health Science is celebrating early success through its collaboration with local in vitro fertilisation (IVF) specialist flindersfertility. (The Advertiser)

Read More

flindersfertility Announce Early Success of EmbryoCellect

Apr 07, 2016 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to advise that in vitro fertilisation (IVF) provider flindersfertility has recently publicised the early success of their new PGS service offered in collaboration with RHS using EmbryoCellect™.

Read More

Adelaide’s RHS gears up for new product launch (The Advertiser)

Feb 01, 2016 -

Publicly listed Adelaide biotech company Reproductive Health Science is just months away from expanding its IVF expertise into other DNA testing areas with the launch of a new product.

Read More

RHS expands Australian Pre-Implantation Genetic Screening (PGS) services

Nov 12, 2015 -

Reproductive Health Science Ltd (RHS or the Company) is pleased to announce that it has entered into a PGS service provision agreement using EmbryoCellect™ with another Australian IVF provider. This follows the establishment of service agreements with FlindersFertility and Morula IVF as previously announced and RHS continues discussions with other Australian IVF providers considering PGS service provision.

Read More

First EmbryoCellect™ training in PGS for IVF providers successfully completed

Aug 28, 2015 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that it has completed its first EmbryoCellect™ training in PGS (Pre-implantation Genetic Screening) for IVF providers.

Read More

Adelaide IVF kit maker signs up China distributor (Advertiser)

Jul 31, 2015 -

ADELAIDE biotech company Reproductive Health Science has signed up a distributor in China to sell its pre-implantation genetic screening kits into the world’s largest IVF market.

Read More

RHS signs with Medicare for distribution of EmbryoCellect™ in China, Hong Kong and Macau

Jul 14, 2015 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) is pleased to announce that it has signed an exclusive distribution agreement with Medicare International Trading Limited for the sale of EmbryoCellect™ in China, Hong Kong and Macau. Medicare is based in Hong Kong and distributes in mainland China through its Chinese company, Miaoquan Enterprise, which is based in Shenzhen. Miaoquan is a key distributor in the field of assisted reproductive medicine, distributing a range of consumables and equipment in these territories for many major international suppliers.

Read More

IVF kit maker gears up for big product boost (Advertiser)

Jul 14, 2015 -

ADELAIDE-based Reproductive Health Science is gearing up to support two key initiatives within weeks to boost the uptake of its pre-implantation genetic screening kit for in-vitro fertilisation patients.

Read More

RHS to facilitate training in PGS for IVF providers

Jul 09, 2015 -

Following on from the ESHRE meeting, further industry interest has culminated in RHS agreeing to facilitate training programmes in the use of EmbryoCellect™ in PGS (Pre-implantation Genetic Screening) for IVF clinics from various jurisdictions.

Read More

RHS Continues Global Launch Of IVF Product (Bioshares)

Jun 05, 2015 -

Reproductive Health Science (RHS) made a backdoor listing on the ASX last year at 20 cents a share. The company markets EmbryoCellect, a product which allows correct chromosome composition to be assessed in embryos from a single cell.

Read More

Reproductive Health Science’s Goal: Lift Success Rates for IVF (Bioshares)

Nov 29, 2014 -

Reproductive Health Science specialises in the genetic analysis of DNA that can obtained from a single cell. RHS has been one of just a few companies to overcome the amplification problem that stems from having only a small amount of DNA as a starting point for analysis.

Read More

IVF Test (9 News, Adelaide)

Jun 23, 2014 -

A locally developed screening test is promising to boost the success rates of IVF.

Read More

Adelaide biotech kit to improve IVF success (The Lead)

May 13, 2014 -

A screening kit developed by Adelaide biotech start-up Reproductive Health Science will reduce heartache and financial burden for couples seeking to become parents through IVF.

Read More